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A szepszishez és egyéb súlyos, kritikus állapotokhoz társuló
neuromuscularis tünetek nem ritka és újonnan felismert
jelenségek, ennek ellenére a mindennapos klinikai gyakor-
latban kevés jelentôséget tulajdonítanak nekik. A kritikus
állapothoz társuló polyneuropathia (CIP) és myopathia (CIM)
a szeptikus betegek közel felét érinti. Ezeket a betegeket
nehezebb leszoktatni a lélegeztetôgéprôl, ezáltal megnyúlik
az intenzív osztályos és a kórházi tartózkodásuk ideje, ami
mind a beteg, mind az egészségügyi ellátórendszer szem-
pontjából kedvezôtlen.
A közlemény célja, hogy összefoglaljuk a CIP/CIM pato -
fiziológiai hátterét, a diagnosztikai lehetôségeket, áttekintést
nyújtsunk a preventív és terápiás lehetôségekrôl és felhívjuk
a figyelmet ezekre a kórképekre, valamint a korán
megkezdett kezelés fontosságára. 
Kulcsszavak: kritikus állapothoz társuló polyneuropathia,
kritikus állapothoz társuló myopathia, szepszis, patofiziológia,
fizikoterápia
Neuromuscular disorders complicating sepsis and critical ill-
ness are not new and scarce phenomena yet they receive lit-
tle attention in daily clinical practice. Critical illness polyneu-
ropathy and myopathy affect nearly half of the patients with
sepsis. The difficult weaning from the ventilator, the pro-
longed intensive care unit and hospital stay, the larger com-
plication and mortality rate these disorders predispose to,
put a large burden on the patient and the health care sys-
tem.
The aim of this review is to give an insight into the patho-
physiological background, diagnostic possibilities and
potential preventive and therapeutic measures in connection
with these disorders to draw attention to their significance
and underline the importance of preventive approach. 
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en first described in the 1980s1–3, critical illnesspolyneuropathy (CIP) and myopathy (CIM) were
thought to be scarce complications of critical illness
but in line with the development of intensive care
and decreasing in-hospital mortality, thirty years’
research has proven that they affect nearly half of
the critically ill patients. The generalized muscle
weakness affecting primarily the limb and respira-
tory muscles presents in difficult weaning from the
ventilator and prolonged immobilization with con-
secutive complications. Beside short term compli-
cations, critical illness neuromuscular disorders
predispose to protracted physical disability,
increase hospital costs and set a severe social bur-
den. With extensive research we are starting to find
out more about the pathophysiological background
and the more we know the more complicated it
seems. Probably the complexity of pathophysiolo-
gy explains why no specific treatment could be
developed so far and this underlines the significance
of certain preventive measures, such as tight glu-
cose control and early rehabilitation which have
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been shown to be effective in decreasing the inci-
dence and severity of CIP and CIM. The aim of the
present work is to summarize the present knowl-
edge on the pathophysiology and possible diagnos-
tic and therapeutic options and to draw attention to
the clinical importance of this clinical syndrome. 
Historical background
Muscle wasting in connection with critical illness
had already been recognised by Hippocrates and
several great physicians of the last centuries such as
William Osler who wrote about the “rapid loss of
flesh and strength” in life threatening infections in
18924–6. Hence until the middle of the 20th century
the early mortality rate of infectious diseases and
critical conditions was so high that there was no
time for neuromuscular complications to develop.
With the evolution of modern intensive care the
(early) mortality of sepsis has decreased significant-
ly but parallel to this, ICU-acquired complications
and comorbidities have become apparent.
In 1977 MacFarlane and Rosenthal reported on
electrophysiologically verified severe myopathy
presenting in the form of quadriplegia in a patient
with status asthmaticus7. In the ‘80s Bolton et al.
were the pioneers to report patients with weaning
difficulty, acute onset paresis and primary distal,
axonal degeneration of motor and sensory nerve
fibres1. The 1990s was the decade of etiological
debates. It took time to differentiate the newly dis-
covered neuromuscular disorder from Guillain-
Barré syndrome (GBS)3, and to clarify the role of
neuromuscular blocking agents (NMBAs) as well
as steroids in its pathogenesis. The millennium
brought the spread of portable electrophysiological
devices which made early electrophysiological
examinations possible without imposing the risk of
intrahospital transport. However, extensive re -
search has been set back by the lack of commonly
applied nomenclature. Authors used different terms
and criteria to describe nearly the same conditions.
Finally in 2009, a round table conference was held
in Brussels where the term intensive care unit-
acquired weakness (ICUAW) was introduced and
within this critical illness polyneuropathy, critical
illness myopathy and in case of coexistence critical
illness neuromyopathy (CINM) were defined6.
Incidence
Due to the numerous terms used and the differences
in diagnostic criteria the incidence of CIP and CIM
is still unknown. In the beginning, mainly polyneu-
ropathy was in the focus of research but recent stud-
ies suggest that pure CIM might be more frequent
than pure CIP8, 9 and their coexistence is seen in
many cases8–10. Overall estimates have ranged
between 13-89%. In the 2011 review by Latronico
and Bolton11 the incidence was estimated in differ-
ent patient populations as follows: in patients with
mechanical ventilation of 4-7 days duration or with
increased risk of developing multi-organ failure
(MOF) it was 25-33% based on clinical assess-
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ABBREVIATIONS
AKT: v-akt murine thymoma oncogene homologue 1 
protein kinase B
AMPK: 5’ adenosine monophosphate-activated protein 
kinase
ARDS: adult respiratory distress syndrome
ATP: adenosine-triphosphate
CIM: critical illness myopathy
CINM: critical illness neuromyopathy
CIP: critical illness polyneuropathy
CMAP: compound muscle action potential
DMS: direct muscle stimulation
GBS: Guillain-Barré snydrome
GLUT-4: glucose transporter 4
ENG: electroneurography
EMG: electromyography
EMS: electrical muscle stimulation
FOX-O: forkhead transcriptional factor
ICU: intensive care unit
ICUAW: intensive care unit-acquired weakness





MAFbx: atrogin-1, muscle atrophy F-box protein
MOF: multi organ failure
MRC: medical research council
mRNA: messenger ribonucleic acid
mTOR: mammalian target of rapamycine
MUP: motor unit potential
MURF-1: muscle ring finger ubiquitin ligase
NMBA: neuromuscular blocking agent
PDK-4: pyruvate-dehydrogenase kinase 4
PI3-k: phosphatidylinositide 3-kinase
SIRS: systemic inflammatory response syndrome
SNAP: sensory nerve action potential




4E-BP1: eukaryotic translation initiation factor 
4E-binding protein 1
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ment12–14 and 30-85% based on electrophysiologi-
cal examination8, 15, 16. Incidence was reported
between 34-60% in patients with adult respiratory
distress syndrome (ARDS)17, 18, 24-77% in those
with longer (>1week) ICU stay19–22, 56-80% in
those with MOF with or without sepsis or systemic
inflammatory response syndrome (SIRS)16, 23–25, and
100% in those with septic shock26, severe sepsis and
coma27. The 2009 Brussels criteria might help to
have a clear picture on the incidence6 which is
important in the scope of the worse prognostic and
outcome characteristics of polyneuropathy8, 9.
Diagnostic methods
CLINICAL ASSESSMENT
Both CIP and CIM are primary direct consequences
of SIRS and sepsis, hence it is crucial to exclude
other pre-existing neuromuscular disorders before
the final diagnosis. For this reason, a thorough
review of medical records, time course of symp-
toms and confounders is inevitable.
Both CIP and CIM present in the form of gener-
al weakness predominantly affecting the limbs and
respiratory muscles and the diaphragm. Facial mus-
cles innervated by the cranial nerves are usually
spared, if affected those are rather signs of myopa-
thy not neuropathy28. The weakness is symmetrical
and generally more pronounced in the lower
extremities (length-dependent pattern in CIP29, 30)
but CIM might present proximal as well28. Deep
tendon reflexes are usually decreased or absent but
can be preserved. In pure CIP hypaesthesia may be
present but paraesthesia or allodynia are not typical
like in other sensory-motor axonal type polyneu-
ropathies. Typically the patient reacts on exerted
pain stimulus administered on the nail with facial
grimacing but no movement in the limbs is seen. In
CIM sensation is usually spared.
For quantification of muscle strength the
Medical Research Council (MRC) scoring system
is used widely due to its simplicity and its fair inter-
observer reliability31. It grades the strength of 3 pre-
defined muscle groups in each extremity from 0 to
5 that gives a total of 60 points. A sum of <48 or an
average score of <4 in each muscle group indicates
ICUAW.
For objective assessment of maximum voluntary
muscle contraction force two devices are used6, 32.
The standard hand dynamometer evaluates hand
grip strength on a calibrated continuous scale while
the genioglossus myometer measures the maximum
tongue protrusion force. The limitation of all clini-
cal tests is that they require an alert and cooperative
patient which is hard to achieve even with the latest
sedation protocols favouring light sedation with
daily interruption of sedatives33. MRC scoring is
applicable for a crude assessment of muscle
strength, the used scale is nonlinear. It does not
measure distal muscle function like hand grip
strength, which is usually affected first in the course
of critical illness. Dynamometers and myometers
are far more precise. Dynamometer measures distal
muscles which show a good correlation with the
MRC scores34, but they are less suitable for assess-
ing the function of very weak muscles (MRC 1-3)
and require costly equipment.
Objective techniques to assess muscle force
through evoking contractions via electrical or mag-
netic stimulation32 are not widely applied at present
due to their limited regular availability at the ICUs.
ELECTROPHYSIOLOGICAL TESTING
Electrophysiology is the gold standard method to
diagnose critical illness neuromuscular disorders.
Beside electroneurography (ENG), needle elec-
tromyography (EMG) and neuromuscular junction
testing, direct muscle stimulation (DMS) is a
recently developed method that enables the electro-
physiologist to examine an unconscious, uncooper-
ative patient, unable to perform voluntary muscle
contraction. Beside the need for cooperation, there
are several other limiting factors of electrophysio-
logical testing. One is the extensive interstitial
oedema, typically present in critically ill patients. It
develops as a result of the hyperkatabolic state,
hypoalbuminemia, transcapillary leak and acts as
an electric seal35, which should make the examiner
more cautious when interpreting low sensory nerve
action potentials (SNAP). Attention should also be
paid to keep proper skin temperature, electrical arte-
facts and electrophysiological alterations in the
medical history.
The clinical and electrophysiological onset time
of the disorders is still a matter of debate, but there
is growing evidence that clinical signs and weak-
ness are well preceded by electrophysiological
alterations. The latter may appear within days after
the onset of SIRS and sepsis8–10, 36. They indicate
temporary functional lesions and turn to definite
morphological lesions in the later phase. These
early alterations are good indicators of the impact
of SIRS and sepsis and good predictors of higher
mortality and to the development of CIP and 
CIM10, 37.
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ELECTRONEUROGRAPHY
As CIP is an axonal type sensory-motor neuropathy
it is characterized by amplitude reduction and nor-
mal or near-normal conduction velocity. The distal
latency is within the normal range. The same
applies to CIM that is the reduction of amplitude –
a result of the muscle fibre atrophy – with intact
conduction velocity and distal latency. The charac-
teristic feature of CIM is a longer duration of the
elicited potentials, explained by the varying con-
duction properties of the degenerated muscle fibres
and reduced excitability38, 39. The other difference
between the two disorders is that while in CIP both
motor and sensory parameters are pathological, in
CIM sensory fibres are usually spared.
ELECTROMYOGRAPHY
EMG is performed with a concentric needle electrode
in three stages of muscle contraction: at rest, at mild
and at full voluntary contraction. It is important to
underline, that critically ill patients under mechani-
cal ventilation and sedation or with septic
encephalopathy usually cannot perform proper con-
traction only in a later stage of the disease when they
regain their consciousness. Therefore recruitment
cannot be evaluated in the acute / subacute phase of
the disease. At rest positive sharp waves and fibrilla-
tion potentials characterise both CIP and CIM, repre-
senting muscle denervation and necrosis. The degree
of alterations can vary in different muscles. If the
patient is capable of muscle contraction, motor unit
action potentials (MUAP) can be recorded which
show a myopathic character in CIM with short dura-
tion and low amplitude MUAPs sometimes firing in
short bursts. In CIP MUAP characteristics vary with
time. Acutely normal morphology turns to short
duration, low amplitude, polyphasic MUAPs in the
next weeks30, 40. Classical long duration, high ampli-
tude reinnervating MUAPs can be found no sooner
than the third week after the onset of the disease15, 40.
In neuropathy the interference pattern shows a reduc-
tion while in myopathy early recruitment of MUAPs
appears and the “envelope” amplitude of the maxi-
mal contraction is reduced28, 29.
Phrenic nerve conduction study and diaphragm
myography
On phrenic nerve ENG bilaterally reduced CMAP
amplitudes with normal conduction velocity can be
found2. The inconvenience caused by forced
diaphragm contraction and local irritation by the
stimulating electrode on the neck limits the use of
this technique in the daily clinical routine. Dia -
phragm EMG can be performed from three app -
roaches: a) using transcutaneous surface electrodes.
This is a non invasive technique but positioning of
the electrodes is not easy and other electrical devices
of the ICU may cause artefacts. b) The classical nee-
dle electrode testing of the diaphragm bears the risk
of several complications, like pneumothorax, liver
puncture, etc. and it is difficult to interpret but this is
the most precise technique. Short duration, low
amplitude MUPs can be expected here as well. c)
Diaphragm MUPs can be also collected with a set of
ring electrodes placed on a special nasogastric or
oesophageal tube. The key point of this non-invasive
inner surface electrode testing is also positioning41. 
Examination of neuromuscular transmission
Repetitive nerve stimulation, single fibre EMG and
TOF (train-of-four) testing play a role in the exclu-
sion of other diseases (myasthenia gravis) or drug
effects (eg. neuromuscular blocking agents) caus-
ing weakness through the blocking of neuromuscu-
lar transmission.
Direct muscle stimulation
The technique of direct muscle stimulation was
developed by Rich et al. to overcome the problem
of eliciting voluntary muscle contraction in a non-
cooperative patient42, 43. It compares the CMAP
amplitudes elicited through stimulating the nerve
(nCMAP) and the muscle (mCMAP) itself.
Neuropathy is suspect when the CMAPs elicited
by stimulating the nerve are decreased though they
are preserved when stimulating the muscle. In this
case the ratio of nerve and muscle elicited CMAPs is
<0.5. In myopathy CMAPs are reduced or absent
(<3mV) both by stimulating the nerve or the muscle
signing the decreased excitability of muscle mem-
brane. The nerve/muscle ratio is >0.5 (Table 1.).
NERVE AND MUSCLE BIOPSY
Histology helps to decide in questionable cases but
it is no longer obligatory for diagnosis, or rather the
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Table 1. Differential diagnostic tool to CIP and CIM




nCMAP / mCMAP <0.5 >0.5
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indication and prognostic value is not clarified yet.
While electrophysiological alterations appear early
in the course of critical illness, histological alter-
ations turn up in the later phase. In case of CIP
nerve histology shows primarily distal axonal
degeneration involving both motor and sensory
fibres without sign of demyelination or inflamma-
tion1. Central nervous system histology revealed the
chromatolysis of anterior horn cells that is the dis-
integration of the chromophil substance, indicating
the exhaustion of the cell or the damage to the
axon30. Muscle histology shows denervation dam-
age of type I and II muscle fibres and also myopath-
ic characteristics27, 30. Later in the course of CIP,
while recovery is ongoing, muscle biopsy will show
grouped atrophy of the muscle fibres.
In CIM a mixed histological picture of acute
necrosis with regeneration, selective loss of thick
filaments (myosin) and atrophy of type II (fast
twitch) muscle fibres can be seen27, 44. The selective
loss of myosin signed by the loss of myofibrillar
adenosine triphosphate on immunohistology is so
characteristic that it led to the term “thick filament
myopathy”45.
ULTRASONOGRAPHY
In recent years attention has turned to assessing
muscle mass loss in ICU patients46. Presently B-
mode ultrasonography (US) of rectus femoris (RF)
muscle seems to be the most suitable technique. RF
is the largest muscle of the body and was shown to
have good correlation with lean body mass47. US
was proven to be as accurate as magnetic resonance
imaging beside being portable, non-invasive, easy
to use and cost effective48. However it is yet to be
determined if cross sectional area46, 49 or muscle
layer thickness47, 50 of rectus femoris muscle is the
more reliable parameter for monitoring, which is
less affected by interstitial oedema. 
LABORATORY TESTING
Elevated serum creatine kinase levels are reported
especially in the necrotizing type of CIM51, 52 but the
kinetics of serum level and the sensitivity is poorly
studied.
Differential diagnosis
As mentioned before, the exclusion of other dis-
eases resulting in acute onset tetraparesis is crucial
to achieve diagnosis. Impairment of neuromuscular
transmission can be excluded with simple electro-
physiological testing (eg. TOF stimulation or repet-
itive nerve stimulation) and the review of patient
history concerning NMBAs, chemotherapy, anti-
retroviral drug administration. Apart from critical
illness, several central nervous system disorders
may also result in generalized muscle weakness.
Myopathy may be caused – among others – by elec-
trolyte disturbances (hypokalemia, hypophos-
phatemia), drugs (statins and fibrates). The so called
propofol infusion syndrome presents with severe
metabolic acidosis, cardiac failure, hypertriglyceri-
daemia and rhabdomyolysis along with a conse-
quent renal failure. It develops in patients receiving
high doses of propofol (5 ml/kg/h) for more than
two days53.
The classical differential diagnostic entity was
the Guillain-Barré syndrome which presents also
with acute onset tetraparesis, but certain clinical,
laboratory and electrophysiological features help
differentiation. These are the ascending characteris-
tic, involvement of cranial and autonomic nerves,
delayed onset time, elevated cerebrospinal fluid
protein content and demyelinating characteristics
on ENG (except for the axonal subtypes of GBS)54. 
The common diabetic and alcoholic polyneu-
ropathies may mimic the electrophysiological char-
acteristics of CIP and give false positive diagnosis
especially when there is no documentation in the
previous history. 
Pathophysiology
The pathophysiology of critical illness associated
neuromuscular disorders is complex. They are no
longer handled as isolated events, rather they are an
integral part of the process leading to multiorgan
dysfunction and failure and this way, the mutual
and additive role of microcirculatory, cellular and
metabolic pathophysiological mechanisms is pre-
sumable11.
It was previously described in 1996 that electro-
physiological alterations precede morphological
deterioration27 and emerging evidence suggests that
definitive morphological lesions are established by
functional failure. Yet, it is still undiscovered how
the peripheral nerve and muscle exhibit a rapid
onset of breaking down and this functional problem
can turn out to be reversible55.
One explanation is the concept of sepsis-induced
bioenergetic failure introduced by Bolton et al. in
the 1990s which is still relevant today and grossly
describes the pathophysiological process. The key
point is that excitable tissues such as the nerves and
muscles spend much of their energy on sustaining
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excitability and function hence they are prone to
develop dysfunction early in case of reduced ener-
gy supply and use29. 
Microcirculatory dysfunction is known to be a
major pathophysiological factor in the development
of sepsis-associated multiorgan failure56–58. The
decrease in the number of perfused capillaries and
the heterogeneity of microvascular circulation lead
to alterations in oxygen extraction and tissue
hypoxia in sepsis59, 60. These microcirculatory
changes can resolve rapidly in response to adequate
therapy but if they persist they predispose to higher
mortality11, 57, 61, 62.
Mitochondrial dysfunction provoked by stress
hormones, inflammatory cytokines, insulin resist-
ance, reactive oxygen species or nitrous oxide also
plays a pivotal role in the pathogenesis of cellular
and organ failure through reduced adenosine-
triphosphate (ATP) biosynthesis, energy generation
and use63, 64. Brealey et al. found a correlation
between muscle ATP concentration, mitochondrial
dysfunction and the severity of septic shock, sug-
gesting that bioenergetic failure is an important
pathophysiological mechanism for muscle and
multi organ dysfunction65. Furthermore, restoration
of mitochondrial biogenesis, which maintains nor-
mal mitochondrial number, structure and function
was found to be an important factor favouring sur-
vival66, 67.
Tumor necrosis factor alpha (TNF-α) and inter-
leukin-6 (IL-6) are known to suppress the insulin
effect through the direct inhibition of the Akt sig-
nalling process culminating in peripheral insulin
resistance and cellular energy depletion. Constatin
et al. found a significant upregulation of muscle
pyruvate dehydrogenase kinase 4 (PDK4) mRNA
and protein expression in critically ill patients,
pointing to the inhibition of muscle carbohydrate
oxidation in these patients68, 69. Weber-Carstens et
al. described faulty glucose transporter-4 (GLUT 4)
disposition and diminished glucose utilization in the
muscle of critically ill patients70. They explained the
impaired transposition of the GLUT 4 transporter
from perinuclear space to sarcolemma with the
impairment of the insulin signalling pathway and
the dysfunction of an AMPK energy sensor as a
result of the lack of metabolic stimulation caused
by the absence of muscle contraction. 
Epi- and endoneurial vessel and concomitant
leukocyte activation shown by increased E-selectin
expression on the endothelial surface lead to the
cessation of vascular autoregulation, endoneurial
oedema and the accumulation of further cytopathic
factors in the perineurial spaces71. Hyperglycemia
and hypoalbuminaemia can further enhance these
processes which finally lead to ischemic hypoxia of
the peripheral nerves even if oxygen supply is ade-
quate8, 11, 23, 29. Beside the onkotic effects of the high
serum glucose level, advanced glycation end-prod-
ucts induce basement membrane hypertrophy in
endoneurial microvessels and disrupt the blood-
nerve-barrier by stimulating the release of trans-
forming growth factor beta and vascular endothe-
lial growth factor by pericytes72.
The next step in the pathophysiological cascade
to be blamed for early electrophysiological distur-
bances is “channelopathy”. Energy depletion leads
to the insufficiency of membrane voltage-depend-
ent sodium channels, that results in a shift of the
voltage dependence of sodium channel fast inacti-
vation towards more negative potentials73–75. The
depolarization of resting membrane potential due to
endoneurial hyperkalaemia or hypoxia can also be
accounted for the hypo-, inexcitability of peripheral
nerves and muscles43, 76. This similar appearance of
channel dysfunction further supports the unifying
hypothesis of CIP and CIM as different manifesta-
tions of one disorder11 but in vivo findings are yet
to be verified in humans.
The prominent muscle wasting in septic patients
is the result of the alterations in the balance of mus-
cle protein synthesis and muscle protein break-
down. 
In healthy volunteers bed rest immobilization
itself caused rapid muscle loss within a week, most
prominently in the lower limbs77. In septic patients
immobilization due to bed rest is aggravated by
sedation and accompanied by insulin resistance and
release of septic cytokines which are also inhibitory
factors of muscle protein synthesis. Consequently
the loss of lean body mass in critically ill patients
was 1-1.6% per day, 7% per week in three weeks
observational studies78, 79 and 16-20% on ultrasound
measurement in the first week in patients with sep-
tic shock80.
Muscle protein synthesis is promoted via the
PI3-K/AKT/mTOR pathway which is activated by
local IGF-1 and nutrients and act through the initia-
tion of several translational factors. Amino acids,
especially branched-chain leucin, are known to
stimulate muscle protein synthesis via both insulin-
dependent (through PI3-K receptor) and insulin-
independent mechanisms81. Yet in sepsis a leucin-
resistance through the defect in leucin induced
translation initiation has been observed82. Septic
cytokine production, namely IL-1, IL-6, TNF-α
directly inhibit the PI3-K/AKT/mTOR pathway
with the deactivation of AKT protein kinase B
resulting in decreased muscle protein synthesis69.
Decreased mTOR kinase activity was evidenced by
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reduced phosphorylation of both eukaryotic initia-
tion factor (eIF)4E-binding protein (BP)-1 and ribo-
somal S6 kinase (S6K)183.
The physiological role of the shift toward
marked degradation of muscle fibres in the septic
patient is to liberate energy and substrates for glu-
coneogenesis and synthesis of acute phase proteins.
There are three main proteolytic ways acting in
the process of critical illness associated muscle
wasting (calpain-caspase system - CCS, ubiquitin-
proteasome system - UPS, lysosomal autophagy
system - LAS). The CCS is responsible for the initi-
ation of breakdown of muscle fibres through releas-
ing actin and myosin fibres from myofilaments thus
exposing them to further cleavage by the protea-
some system. Calpains are cystein proteases which
are activated by the elevation of cytosolic Ca2+
level, in this case promoted by inflammatory
cytokines84. The ATP-dependent UPS is responsi-
ble for the large-scale degradation of damaged
myofibrilla. Proteins ligated with the polypeptide
ubiquitin are destined to breakdown by the 20S core
of the 26S proteasome system. The key elements of
the ligation process are the muscle specific MAFbx
and MURF-1 E3 ubiquitin ligases which are
induced by the FOX-O transcription factor just like
the cathepsin B, D, and L enzymes in the LAS69, 85.
The role of the LAS system in the critically ill has
not been clarified yet: autophagy either protects
against the collection of toxic myofibrillar aggre-
gates, which initiate muscle dysfunction, or it exac-
erbates the loss of the myofibrillar apparatus to
induce atrophy86.
At the moment, these molecular pathways seem
to be responsible for septic muscle protein synthe-
sis and breakdown but to what extent and in what
temporal dispersion that is yet to be elucidated.
After the standardized environment and results of
animal research, human research produces diver-
gent and sometimes contradictory results69, 70, 85, 87
concerning gene expressions, protein activities and
the clinical relevance of the different biochemical
mechanisms. In a comprehensive molecular study
Constantin et al. showed the simultaneous down-
regulation of signalling proteins thought to increase
muscle protein synthesis (Akt1, mTOR, 4E-BP1,
p70s6k) and a parallel activation of molecular path-
ways driving muscle protein breakdown (MAFbx,
MuRF1, 20S proteasome, cathepsin-L). Yet, the
catabolic changes were paralleled by initiation of a
cellular program of anabolic restoration at the tran-
scriptional level, as suggested by a significant
increase in mRNA of anabolic factors69. Compared
to this Jespersen et al. found decreased MuRF1/
MAFbx levels and a higher Akt/mTOR/S6k/4E-
BP1 anabolic signalling expression and in septic
patients what they explained with the exogenous
administration of insulin which is an activator of
this anabolic pathway through receptor PI3-K87. 
Beside the loss of contractile elements (over-
whelmingly myosin loss), mitochondrial dysfunc-
tion and muscle membrane inexcitability, oxidative
stress, impaired excitation-contraction coupling
also contribute to the impaired force-generating
capacity of muscle in critically ill patients88. 
Risk factors
Over the years several factors have been suspected
to be responsible for the development of CIP and
CIM, the role of some factors has still remained
debatable. The severity and duration of SIRS and
sepsis12, 14, 22, 25, 89–91, number of organ failures25, 89, 90,
duration of vasopressor and catecholamine sup-
port20, duration of ICU stay20, 23, renal failure14,
hyperglycaemia17, 20–23, 89, 90, low serum albumin23, 89,
92, hyperosmolality93, parenteral nutrition88, 93, neu-
rological failure94, immobility89, 95, female sex12, 89
presently seem to be evident risk factors.
Three prospective observational studies conclud-
ed that corticosteroids had a negative effect con-
cerning the development of CINM12, 96, 97, yet sever-
al others reported that they had no effect14, 20, 93, 98–100
especially if tight glucose control was kept. One
study showed that they were protective probably
though decreasing the cathecholamin and vaso-
pressr need21. 
Aminoglycoside antibiotics were also identified
as risk factors in some studies15, 22, 37 but not in oth-
ers11, 12, 17, 20, 21, 23, 93, 101.
In the 1980s and 1990s prolonged application of
neuromuscular blocking agents was considered as a
causative factor in the development of ICUAW93,
102–105. In line with the introduction of intermittent
administration NMBA rptpcols, and Hoffman-elim-
inating short acting agents the direct causative con-
nection has become questionable although immo-
bility caused by NMBAs cannot be disregarded.
Renal replacement therapy was also found to be
a protective93 and causative factor106–108 at the same
time, but it is still a question whether renal replace-
ment therapy or renal insufficiency itself is to be
blamed.
Therapy
Up to the present day no specific, evidence-based
effective therapy has been developed for the man-
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agement of critical illness-associated neuromuscu-
lar disorders. No hormonal therapies, nutritional or
antioxidant supplements could prove to be decisive,
yet several supportive and preventive measures
have been found to be effective.
Since the large-scale prospective, randomized,
controlled trial of Van den Berghe et al, where
intensive insulin therapy reduced the risk of CIP
and the duration on mechanical ventilation beside
many other ICU complications20 and knowing the
pathological effects of hyperglycaemia there is no
need to emphasize the significance of strict glucose
control in the critically ill. Only the original Van
den Berghe target range (4.4-6.1 mmol/l) has been
modified to <10 mmol/l108 since the former proto-
col had turned out to increase the number of hypo-
glycaemic episodes and ICU mortality109.
One of the major advances in rehabilitation of
these patients is the shift toward preventive app -
roach. Rehabilitation started early in the ICU after
reaching hemodynamic stability with repeated daily
passive mobilization, early physical and occupa-
tional therapy up to the patient’s physical and men-
tal status is associated with better outcomes110, 111.
In connection with this we have to emphasize the
role of daily interruption of sedation and the spon-
taneous breathing trials. These measures help to
preserve muscle mass, improve functional inde-
pendence, shorten ventilator dependency, delirium,
ICU and hospital stay33, 112, 113.
A promising advancement of the last two years
was the introduction of electric muscle stimulation
(EMS) in the ICU114. EMS was proved to improve
muscle strength and muscle mass in chronic
obstructive pulmonary disease and chronic heart
failure patients115–119. In the critically ill its use is
not circumscribed yet69, 120–123. So far it seems to
stimulate biochemical mechanisms which are
responsible for muscle protein synthesis and to
stimulate muscle glucose uptake through the facili-
tation of GLUT-4 transposition to the sarcolem-
ma70, this way it can improve insulin resistance.
Gerovasili et al. found that EMS might affect bene-
ficially local and systemic microcirculation based
on near-infrared spectroscopy measurement124 and
might help to preserve muscle mass according to
ultrasound measurement121. Routsi et al. found that
daily EMS sessions prevented critical illness neu-
romyopathy120. Several trials are ongoing to clarify
its affectivity and feasibility in preventing muscle
wasting, to elucidate its biochemical effect and to
determine the optimal treatment parameters125, 126.
Presently EMS seems more potent in preserving
muscle strength compared to muscle mass113.
The role of immunoglobulins (IVIG) in the pre-
vention of CIP and CIM is quite contradictory. In a
retrospective chart analysis by Mohr et al. the
administration of high dose immunoglobulin M
(IgM) enriched IVIG was found to be protective101.
Brunner et al. could find no beneficial effect of IgM
enriched IVIG in their prospective randomised con-
trolled double blind trial, however they adminis-
tered IVIG only after the evolution of electrophysi-
ological alterations and in smaller dose than in the
Mohr study127.
Other therapeutic or preventive measures, like
the administration of nutritional (leucin or gluta-
mine supplementation), hormonal (growth hor-
mone, testosterone or oxandrolone administration),
antioxidant supplements have not proved to be
effective so far. 
Conclusions
The aim of this review was to give an insight into
these long known but during daily clinical work
often neglected disorders. Breathing insufficiency
and movement inability as consequences of
ICUAW are major contributors to ICU and hospi-
tal mortality. Along with the development of med-
ical care more lives can be saved but the number
of physically disabled survivors is rising also set-
ting severe social, health care and economical
problems.
The author cannot stress the importance of pre-
ventive approach and early intervention. Early
mobilization and physiotherapy, the application of
liberal sedation protocol and strict glucose control
are proven to be beneficial not only from the aspect
of neuromuscular complications. They favourably
influence the course of critical illness interfering
with septic cascade at multiple sites and thus help
to preserve and/or restore organ function. Rehabi -
litation should start already in the ICU.
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KÖSZÖNJÜK TÁMOGATÓINKNAK!
Támogatói elôfizetôi csomagunkat azért alakítottuk ki, hogy ezzel elhivatott olvasóink 
támogathassák kiadónk munkáját.
Köszönjük azoknak, akik 2014-ben ezt a speciális elôfizetési formát választották. 
2015-ben is számítunk azokra az
olvasóinkra, akik támogatói csomaggal járulnak hozzá jövô évi lapszámaink színvonalas 
megjelenéséhez, a lap fejlesztéséhez.
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